J 2018

MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma

MYTSYK, Yulian, Victor DOSENKO, Yuriy BORYS, Askold KUCHER, Katarina GAZDIKOVA et. al.

Základní údaje

Originální název

MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma

Autoři

MYTSYK, Yulian (804 Ukrajina), Victor DOSENKO (804 Ukrajina), Yuriy BORYS (804 Ukrajina), Askold KUCHER (804 Ukrajina), Katarina GAZDIKOVA (703 Slovensko), Dietrich BUSSELBERG (634 Katar), Martin CAPRNDA (703 Slovensko), Peter KRUŽLIAK (703 Slovensko, garant, domácí), Ammad Ahmad FAROOQI (586 Pákistán) a Manyuk LUBOV (804 Ukrajina)

Vydání

International Urology and Nephrology, Dordrecht, Springer, 2018, 0301-1623

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30217 Urology and nephrology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.596

Kód RIV

RIV/00216224:14110/18:00102916

Organizační jednotka

Lékařská fakulta

UT WoS

000431429000008

Klíčová slova anglicky

Renal cell carcinoma; MiRNA-15a; Biomarker; Diagnosis; Molecular marker

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 10. 2. 2019 16:07, Soňa Böhmová

Anotace

V originále

Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker. In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control. We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E-01 +/- 2.72E-01 vs 1.32E-03 +/- 3.90E-03 vs 3.36E-07 +/- 1.04E-07 RFU, respectively, p < 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p > 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient-0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p < 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955. MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.